Alain Puisieux

List of Publications by Year in Descending Order

115 papers	11,099 citations	44 h-index	105 g-index
132 ext. papers	12,815 ext. citations	9.4 avg, IF	6.01 L-index

#	Paper	IF	Citations
115	ZEB1 transcription factor promotes immune escape in melanoma. **2022**, 10,		4
114	Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.. *BMC Cancer*, **2022**, 22, 526	4.8	0
113	Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.. *European Journal of Cancer*, **2022**, 169, 106-122	7.5	1
112	EMT Transcription Factor ZEB1 Represses the Mutagenic POLΘ-Mediated End-Joining Pathway in Breast Cancers. *Cancer Research*, **2021**, 81, 1595-1606	10.1	11
111	Opposite Roles for ZEB1 and TMEJ in the Regulation of Breast Cancer Genome Stability. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 727429	5.7	1
110	Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis. *Cancers*, **2021**, 13,	6.6	4
109	Zeb1 expression by tumor or stromal cells is associated with spatial distribution patterns of CD8+ tumor-infiltrating lymphocytes: a hypothesis-generating study on 113 triple negative breast cancers. *American Journal of Cancer Research*, **2020**, 10, 3370-3381	4.4	1
108	Ribosomal RNA 2′-O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer. *NAR Cancer*, **2020**, 2, zcaa036	5.2	12
107	Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. *Nature Communications*, **2020**, 11, 3431	17.4	20
106	Assessing Cell Activities rather than Identities to Interpret Intra-Tumor Phenotypic Diversity and Its Dynamics. *IScience*, **2020**, 23, 101061	6.1	1
105	CDYL2 Epigenetically Regulates MIR124 to Control NF-κB/STAT3-Dependent Breast Cancer Cell Plasticity. *IScience*, **2020**, 23, 101141	6.1	6
104	Guidelines and definitions for research on epithelial-mesenchymal transition. *Nature Reviews Molecular Cell Biology*, **2020**, 21, 341-352	48.7	469
103	Quantifying local malignant adaptation in tissue-specific evolutionary trajectories by harnessing cancer's repeatability at the genetic level. *Evolutionary Applications*, **2019**, 12, 1062-1075	4.8	2
102	Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 475, 85-94	5.1	12
101	Cellular Pliancy and the Multistep Process of Tumorigenesis. *Cancer Cell*, **2018**, 33, 164-172	24.3	46
100	Pleiotropic Roles for ZEB1 in Cancer. *Cancer Research*, **2018**, 78, 30-35	10.1	153
99	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. *Scientific Reports*, **2018**, 8, 7386	4.9	7

98	Immunological and classical subtypes of oral premalignant lesions. *OncoImmunology*, **2018**, 7, e1496880	7.2	25
97	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. *Nature Medicine*, **2017**, 23, 568-578	50.5	78
96	A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. *BMC Medicine*, **2017**, 15, 165	11.4	33
95	Destabilization of the TWIST1/E12 complex dimerization following the R154P point-mutation of TWIST1: an in silico approach. *BMC Structural Biology*, **2017**, 17, 6	2.7	1
94	The cell-of-origin dictates the genomic landscape of breast cancers. *Molecular and Cellular Oncology* , **2017**, 4, e1338931	1.2	1
93	Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. *Oncotarget*, **2017**, 8, 2423-2436	3.3	18
92	The Heterodimeric TWIST1-E12 Complex Drives the Oncogenic Potential of TWIST1 in Human Mammary Epithelial Cells. *Neoplasia*, **2016**, 18, 317-327	6.4	4
91	Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. *Clinical Cancer Research*, **2016**, 22, 5564-5573	12.9	71
90	Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 450-60	4	68
89	Sulfur isotope analysis by MC-ICP-MS and application to small medical samples. *Journal of Analytical Atomic Spectrometry*, **2016**, 31, 1002-1011	3.7	24
88	ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. *EMBO Molecular Medicine*, **2016**, 8, 1143-1161	12	78
87	Deciphering the molecular mechanisms underlying the binding of the TWIST1/E12 complex to regulatory E-box sequences. *Nucleic Acids Research*, **2016**, 44, 5470-89	20.1	13
86	TIF1 Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability. *Cancer Research*, **2015**, 75, 4335-50	10.1	22
85	Copper isotope effect in serum of cancer patients. A pilot study. *Metallomics*, **2015**, 7, 299-308	4.5	74
84	Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells. *Nucleic Acids Research*, **2015**, 43, 5838-54	20.1	14
83	TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. *Cancer Letters*, **2015**, 357, 412-418	9.9	34
82	Oncogenic roles of EMT-inducing transcription factors. *Nature Cell Biology*, **2014**, 16, 488-94	23.4	669
81	TWIST1 expression in breast cancer cells facilitates bone metastasis formation. *Journal of Bone and Mineral Research*, **2014**, 29, 1886-99	6.3	54

80	Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer. *World Journal of Clinical Oncology*, **2014**, 5, 311-22	2.5	41
79	Interhelical loops within the bHLH domain are determinant in maintaining TWIST1-DNA complexes. *Journal of Biomolecular Structure and Dynamics*, **2014**, 32, 226-41	3.6	7
78	ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells. *Molecular Cancer*, **2014**, 13, 213	42.1	24
77	Snail family members unequally trigger EMT and thereby differ in their ability to promote the neoplastic transformation of mammary epithelial cells. *PLoS ONE*, **2014**, 9, e92254	3.7	33
76	p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. *Cancer Cell*, **2013**, 24, 318-30	24.3	175
75	A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. *Cancer Cell*, **2013**, 24, 466-80	24.3	352
74	PLA2R1 kills cancer cells by inducing mitochondrial stress. *Free Radical Biology and Medicine*, **2013**, 65, 969-977	7.8	25
73	Tif1 s essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. *Development (Cambridge)*, **2013**, 140, 167-75	6.6	20
72	PLA2R1 mediates tumor suppression by activating JAK2. *Cancer Research*, **2013**, 73, 6334-45	10.1	43
71	Modulation of oxidative stress by twist oncoproteins. *PLoS ONE*, **2013**, 8, e72490	3.7	12
70	Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. *Breast Cancer Research and Treatment*, **2012**, 132, 29-39	4.4	70
69	Impaired IFN- production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. *Cancer Research*, **2012**, 72, 5188-97	10.1	216
68	TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. *PLoS ONE*, **2012**, 7, e29954	3.7	51
67	EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. *PLoS Genetics*, **2012**, 8, e1002723	6	139
66	Variants in the netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer. *Gastroenterology*, **2011**, 141, 2039-46	13.3	27
65	CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. *Blood*, **2011**, 118, 5130-40	2.2	39
64	Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. *Blood*, **2011**, 117, 1673-6	2.2	43
63	Failsafe program escape and EMT: a deleterious partnership. *Seminars in Cancer Biology*, **2011**, 21, 392-6	12.7	23

62	p21(Cip1) regulates cell-substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cells. *European Journal of Cell Biology*, **2011**, 90, 631-41	6.1	4
61	II-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells. *European Journal of Cell Biology*, **2011**, 90, 872-8	6.1	5
60	Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. *Pediatric Blood and Cancer*, **2011**, 56, 757-61	3	24
59	Intensity-dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles. *Genes Chromosomes and Cancer*, **2011**, 50, 178-85	5	18
58	Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. *Epigenetics*, **2011**, 6, 428-39	5.7	59
57	Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. *Journal of Immunotherapy* , **2010**, 33, 591-8	5	28
56	The CD10 enzyme is a key player to identify and regulate human mammary stem cells. *Stem Cells*, **2010**, 28, 1081-8	5.8	63
55	Cancer stem cells: the emerging challenge of drug targeting. *Current Medicinal Chemistry*, **2009**, 16, 394-416	4.5	50
54	Netrin-1 acts as a survival factor for aggressive neuroblastoma. *Journal of Experimental Medicine*, **2009**, 206, 833-47	16.6	96
53	Upstream ORF affects MYCN translation depending on exon 1b alternative splicing. *BMC Cancer*, **2009**, 9, 445	4.8	6
52	Influence of neuroblastoma stage on serum-based detection of MYCN amplification. *Pediatric Blood and Cancer*, **2009**, 53, 329-31	3	24
51	Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. *Nature Immunology*, **2009**, 10, 778-85	19.1	377
50	Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. *Cancer Research*, **2009**, 69, 2000-9	10.1	489
49	Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. *PLoS Genetics*, **2009**, 5, e1000575	6	91
48	Rle de la transition pithlio-msenchymateuse au cours de la progression tumorale. *Bulletin De LnAcademie Nationale De Medecine*, **2009**, 193, 2017-2034	0.1	1
47	Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. *Nature*, **2008**, 455, 967-70	50.4	658
46	Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis. *Journal of Investigative Dermatology*, **2008**, 128, 196-202	4.3	24
45	Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. *Cancer Cell*, **2008**, 14, 79-89	24.3	547

44	Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. *Molecular Cancer*, **2008**, 7, 50	42.1	30
43	Early origin of cancer metastases: dissemination and evolution of premalignant cells. *Cell Cycle*, **2008**, 7, 3659-63	4.7	19
42	Generation of breast cancer stem cells through epithelial-mesenchymal transition. *PLoS ONE*, **2008**, 3, e2888	3.7	1183
41	BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. *Blood*, **2008**, 112, 3154-63	2.2	41
40	Should we consider cancers as embryonic diseases or as consequences of stem-cell deregulation?. *Clinical Medicine Oncology*, **2008**, 2, 363-6		
39	Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. *Human Mutation*, **2007**, 28, 1084-90	4.7	56
38	Weekly administration of paclitaxel induces long-term aneugenicity in nude mice. *Cancer Biology and Therapy*, **2007**, 6, 377-82	4.6	7
37	Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. *BMC Cancer*, **2006**, 6, 216	4.8	19
36	Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. *Human Mutation*, **2006**, 27, 145-54	4.7	70
35	A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. *International Journal of Cancer*, **2006**, 119, 60-6	7.5	9
34	UVB-induced G2 arrest of human melanocytes involves Cdc2 sequestration by Gadd45a in nuclear speckles. *Cell Cycle*, **2006**, 5, 1859-64	4.7	10
33	Metastasis: a question of life or death. *Nature Reviews Cancer*, **2006**, 6, 449-58	31.3	1290
32	p53 as a target for anti-cancer drug development. *Critical Reviews in Oncology/Hematology*, **2006**, 58, 190-207	7	68
31	Mutational targets in colorectal cancer cells with microsatellite instability. *Familial Cancer*, **2006**, 5, 29-34	3	21
30	C. elegans homologue of the Caf1 gene, which encodes a subunit of the CCR4-NOT complex, is essential for embryonic and larval development and for meiotic progression. *Gene*, **2005**, 358, 73-81	3.8	37
29	Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. *Cancer Letters*, **2005**, 225, 111-20	9.9	35
28	Protein chip array profiling analysis of sera from neuroblastoma patients. *Cancer Letters*, **2005**, 228, 91-6	9.9	30
27	The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. *Journal of Cell Science*, **2005**, 118, 1245-53	5.3	19

26	Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. *Journal of Clinical Oncology*, **2005**, 23, 8919-20; author reply 8920	2.2	24
25	Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. *Cancer Cell*, **2004**, 6, 625-30	24.3	208
24	Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. *Human Genetics*, **2003**, 112, 117-23	6.3	81
23	Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine. *Biochemical Pharmacology*, **2003**, 65, 121-9	6	22
22	Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. *BMC Biotechnology*, **2003**, 3, 18	3.5	237
21	Alterations of anaphase-promoting complex genes in human colon cancer cells. *Oncogene*, **2003**, 22, 1486-90	9.2	81
20	Chfr inactivation is not associated to chromosomal instability in colon cancers. *Oncogene*, **2003**, 22, 8956-60	9.2	30
19	Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. *Human Mutation*, **2002**, 19, 108-13	4.7	25
18	Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. *International Journal of Cancer*, **2002**, 97, 439-45	7.5	84
17	BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. *Oncogene*, **2002**, 21, 6772-78	9.2	59
16	Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. *EMBO Reports*, **2002**, 3, 1055-61	6.5	139
15	The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. *Gene*, **2002**, 282, 207-14	3.8	55
14	Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. *Cancer Research*, **2002**, 62, 3646-8	10.1	56
13	BTG gene expression in the p53-dependent and -independent cellular response to DNA damage **2000**, 27, 57-64		71
12	Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. *Oncogene*, **2000**, 19, 2461-4	9.2	21
11	Is the KAI1 metastasis suppressor gene a cellular target of p53? A review of current evidence. *Biochemical and Biophysical Research Communications*, **2000**, 278, 499-502	3.4	15
10	Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families. *International Journal of Cancer*, **1997**, 73, 831-6	7.5	14
9	Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. *Nature Genetics*, **1996**, 14, 482-6	36.3	346

8	Modulation of p36 gene expression in human neuronal cells. *Journal of the Neurological Sciences*, **1995**, 128, 122-33	3.2	11
7	Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. *FASEB Journal*, **1993**, 7, 1407-13	0.9	115
6	p53 mutation in hepatocellular carcinoma after aflatoxin exposure. *Lancet, The*, **1991**, 338, 1356-9	40	387
5	Occurrence of fragmentation of free and combined forms of the beta-subunit of human chorionic gonadotropin. *Endocrinology*, **1990**, 126, 687-94	4.8	49
4	Structural probing of human lutropin using antibodies raised against synthetic peptides constructed by classical and multiple antigen peptide system approaches. *Molecular Immunology*, **1990**, 27, 363-8	4.3	40
3	Characterization of a cleavage product in the human choriogonadotropin beta-subunit. *Biochemical and Biophysical Research Communications*, **1988**, 154, 626-32	3.4	33
2	Biophysical properties of intermediate states of EMT outperform both epithelial and mesenchymal states		3
1	Targeting of TP53-independent cell cycle checkpoints overcomes FOLFOX resistance in Metastatic Colorectal Cancer		2